瑞士 FCC 实验室是 Paul Niehans 百年细胞疗法技术的正统持有方。细胞递送、植物愈伤培养、多肽活性保存，三项技术在这里落地，再写入专为亚洲肌肤准备的配方。The Swiss FCC Lab holds, in the direct line, Paul Niehans’ century of cellular therapy. Delivery, plant callus culture, and the keeping of peptide activity are carried here, then written into a formula made for Asian skin.
接下来的画面是团队合影。细胞疗法这一条线留在原地。What follows is the team portrait. The line of cellular therapy stays.
XINVEN Lab™
瑞士 FCC 实验室Swiss FCC Lab
Paul Niehans 百年细胞疗法技术的全球正统持有方。细胞递送、植物愈伤培养、多肽活性保存，三项技术在这里落地。Holder, in the direct line, of Paul Niehans’ century of cellular therapy. Delivery, plant callus culture, and peptide activity are carried here.
左侧是团队合影。The image is the team portrait.
全球研发首席科学家Chief scientist
Emek Kocatürk Göncü
德国柏林夏里特医学院教授，EADV荨麻疹工作组联合主席。炎性衰老研究二十余年，SCI 引用 5600+，主导配方逻辑与全球功效验证。Professor at Charité Berlin. Co-chair of the EADV urticaria task force. Twenty years in inflammaging, 5600+ citations, leading the formula and its global proof.
中方临床总顾问Clinical advisor, China
赖永贤Lai Yongxian
上海皮肤病医院资深专家。牵头国内临床验证，衔接北京协和、上海九院等三甲医院的专家资源。Senior specialist at Shanghai Skin Disease Hospital. He leads clinical validation in China, linking experts at Peking Union, Shanghai Ninth People’s, and other Grade III-A hospitals.
专家背书Endorsements瑞士 FCC 实验室持有 Paul Niehans 百年细胞疗法。配方在柏林验证，临床在上海展开。The Swiss FCC Lab holds Paul Niehans’ century of cellular therapy. Berlin proves the formula. Shanghai carries the clinic.
研究与现场，收在同一条线上。Research and the clinic close into one line.
专为亚洲肌肤。Made for Asian skin.